Nov 28, 2014
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
Nov 4, 2014
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS
Oct 22, 2014
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program

View All News (+)

Enter Your Email to Sign Up for
iCo Therapeutics Updates

Welcome to iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.   iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO", and on the OTCQX under the symbol “ICOTF”.

Copyright 2010 ICO Therapeutics | Disclaimer